• Baicalin and KEAP1-NRF2/HO-1 Pathway Modulation in Neuroplas

  2026-05-09

  Baicalin, a flavone glycoside from Scutellaria baicalensis, offers unique advantages for modulating neuroplasticity and cancer signaling, with reproducible outcomes in amblyopia and oncology models. APExBIO’s high-purity Baicalin enables advanced experimental designs by ensuring reliable pathway modulation and validated bioactivity.

• H-89 in Osteoblast Research: Precision Tools for cAMP Pathwa

  2026-05-08

  Explore how H-89, a potent cAMP-dependent protein kinase inhibitor, enables advanced dissection of cAMP signaling and metabolic rewiring in osteoblastogenesis. This article offers unique protocol insights and practical guidance for metabolic and bone research.

• Novobiocin: Aminocoumarin Antibiotic for Antimicrobial Workf

  2026-05-08

  Novobiocin enables potent antibacterial, antiparasitic, and antiviral workflows by uniquely targeting bacterial DNA gyrase and Hsp90. This guide translates its dual mechanism and protocol flexibility into reproducible, high-impact experimental strategies, with actionable troubleshooting tips for resistance and advanced phenotypic assays.

• Dye Models Enhance Small Biopsy Detection: Evidence from Pat

  2026-05-07

  This study systematically evaluated the effectiveness of various tissue marking dyes, including merbromin, hematoxylin, eosin, crystal violet, and alcian blue, for improving the visualization and retention of small tissue biopsies during histopathological processing. The findings underscore hematoxylin’s superior balance of visibility and diagnostic non-interference, informing best practices for pre-analytical tissue management.

• Anti-Inflammatory Anti-Angiogenic Stents Combat Tracheal Res

  2026-05-07

  Zhao et al. introduce a dual-action airway stent integrating anti-inflammatory and anti-angiogenic agents to address tracheal in-stent restenosis (TISR). Through advanced electrospinning, the study demonstrates suppression of fibrosis, angiogenesis, and infection, offering translational promise for airway management.

• LLY507 (SKU B6119): Reliable SMYD2 Inhibition in Cancer Rese

  2026-05-06

  LLY507 (SKU B6119) is a highly selective and potent SMYD2 inhibitor, designed to address key challenges in cell viability, proliferation, and cytotoxicity assays. This article provides scenario-driven guidance for optimizing experimental reproducibility and sensitivity using LLY507, with evidence-backed insights tailored to biomedical researchers and lab technicians.

• Early Pheromone Perception Drives Neurodegeneration in C. el

  2026-05-06

  Peng et al. (2023) reveal how early-life exposure to specific pheromones remodels neural development and accelerates adult neurodegeneration in C. elegans. This work elucidates a mechanistic link between environmental chemical cues, altered neurodevelopmental signaling, and the inhibition of neuronal autophagy, with implications for understanding proteostasis and neurodegenerative disease origins.

• Bestatin (Ubenimex): Precision Workflows in MDR & Cancer Res

  2026-05-05

  Bestatin (Ubenimex) is a benchmark aminopeptidase inhibitor, enabling reliable dissection of multidrug resistance and apoptosis pathways with nanomolar precision. This guide synthesizes best practices, troubleshooting insights, and advanced use-cases, drawing from the latest cancer research and APExBIO's trusted formulations.

• Reassessing Chloroquine's Antiviral Potential in COVID-19

  2026-05-05

  The commentary by Touret and de Lamballerie critically evaluates the preclinical and clinical evidence for chloroquine as an antiviral agent against SARS-CoV-2. Their synthesis underscores the discrepancy between promising in vitro results and limited or adverse outcomes in animal models and human trials, highlighting the importance of rigorous translational evaluation before clinical adoption.

• Biomimetic Chromatography for Lung Drug Permeability Modelin

  2026-05-04

  This study evaluates biomimetic open tubular capillary electrochromatography (OT-CEC) and immobilised artificial membrane chromatography (IAM-LC), both coupled with mass spectrometry, for predicting pulmonary drug permeability. The findings highlight the strengths and limitations of each approach, providing a robust, high-throughput platform for early-stage drug development and permeability screening.

• Propidium Iodide: Applied Workflows for Cell Viability & Apo

  2026-05-04

  Propidium iodide (PI) from APExBIO empowers researchers with robust, quantitative cell viability and apoptosis detection across diverse biomedical workflows. This article unpacks hands-on protocols, advanced applications, and troubleshooting strategies that set PI apart as a premier DNA intercalating dye for high-impact cellular research.

• Etoposide (VP-16): Applied Workflows for DNA Damage Assays

  2026-05-03

  Etoposide (VP-16) unlocks precise DNA damage and apoptosis induction workflows for cancer research, with robust, reproducible protocols and troubleshooting strategies. This article details APExBIO's validated approaches, highlights reference-driven innovations, and guides researchers through advanced applications, optimization, and future perspectives.

• Transfection Potency and mRNA Integrity: Firefly Luciferase

  2026-05-02

  Explore how Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) leverages advanced modifications and buffer optimization to maximize transfection potency and bioluminescent assay reliability. This article reveals new scientific insights that go beyond current guides, empowering researchers in gene expression and in vivo imaging.

• Calnexin’s Role in CFTR Variant Rescue: Systematic Insights

  2026-05-01

  Tedman et al. systematically investigated the impact of the chaperone calnexin on the expression and pharmacological rescue of over 200 clinical CFTR variants. Their deep mutational scanning approach revealed that calnexin is critical for both CFTR surface expression and corrector drug efficacy in a domain- and mutation-specific manner, providing actionable insights for personalized cystic fibrosis research.

• EPZ5676: DOT1L Inhibitor Optimizing Leukemia Assays & Beyond

  2026-05-01

  EPZ5676, a potent DOT1L inhibitor offered by APExBIO, delivers unmatched selectivity and nanomolar potency for dissecting epigenetic mechanisms in MLL-rearranged leukemia. This article bridges foundational insights and advanced troubleshooting, empowering researchers to streamline H3K79 methylation assays and innovate translational workflows.

15123 records 1/1009 page Next 12345 下5页 Last page